Sten Stovall

Latest From Sten Stovall
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk, Evotec Link Around Chronic Kidney Disease
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
Antifungal Specialist F2G Gets Near $61m Financing
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
BetterLife/Altum Merger ‘Triggered By Early COVID-19 Promise’
Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.